Request a demo specialized to your need.
6 Findings That Show Up Again and Again in FDA and EMA Trial Inspections
FDA conducted over 1,000 Bioresearch Monitoring inspections in a recent fiscal year, and roughly eight in ten targeted clinical investigators, sponsors, CROs, and IRBs directly, according to a Goodwin analysis of FDA inspection data. A comparative study of FDA and EMA inspection findings, published in PMC, found close to 90% agreement between the two agencies on which deficiency categories show up most for clinical investigator and sponsor/CRO inspections.
Taken together, these separate analyses spanning different time periods and methodologies point to the same handful of problems recurring across trials, regardless of therapeutic area, sponsor size, or country.
This isn't one official FDA-published ranking; it's a synthesis of what several recent, credible inspection-findings analyses independently keep finding. That consistency across independent sources is itself useful information: if the same categories keep appearing across separate studies, they're not random bad luck they're predictable, which means they're preventable if caught early enough. Here are the six that repeat most often across these analyses, and the point in a trial's life where each one was already visible before an inspector ever found it.
1. Failure to Follow the Investigational Plan
Protocol deviations visits outside the allowed window, procedures done out of sequence, dosing that doesn't match what the protocol specifies. Individually, most are minor. Cited as a pattern across a site or a study, they become the single most common finding in clinical investigator inspections.
The deviation itself usually isn't discovered at inspection it happened at a specific visit, on a specific date, and was either logged and addressed close to that moment, or wasn't discovered until someone reviewed the record much later.
2. Inadequate or Inaccurate Study Records
The second most commonly cited FDA deficiency: case histories and study records that are incomplete, inconsistent, or don't hold up when compared against the source. This is rarely one dramatic error. It's usually the accumulation of small gaps a missing signature here, a form filled in late there that only becomes visible when someone finally cross-references the full record.
3. Missing Required Elements in Informed Consent
A consent form missing a single required element under 21 CFR Part 50 is enough to become a numbered observation on a Form 483. Consent documentation is created once, at a specific visit, by a specific person which means the gap exists from the moment it's signed, not from the moment an inspector reviews it.
4. Trial Management Deficiencies
For sponsor and CRO inspections specifically, trial management issues are the most common finding category gaps in oversight, monitoring that didn't happen on the expected cadence, or action items that were identified but never closed out. These are oversight failures, not data failures, which makes them about process as much as any individual record.
5. Documentation and TMF Gaps
This is EMA's single most common finding category for both investigator and sponsor/CRO inspections, with meaningful overlap in FDA findings too. A document that's missing, misfiled, or simply hasn't caught up to where the trial actually stands doesn't announce itself it sits quietly until someone goes looking for it, usually during an inspection prep scramble.
6. Delegation and Investigator Obligation Gaps
Failure to comply with the obligations an investigator formally signs up for delegation logs that don't reflect who actually performed a task, or responsibilities that shifted without the paperwork catching up. Like consent, this is a point-in-time gap: the mismatch exists the day it happens, not the day someone checks the log against reality.
What All Six Have in Common
Every one of these findings has a specific moment where it first became true a visit, a signature, a missed monitoring cycle, a document that didn't get filed. None of them are discovered at that moment by default. They're discovered whenever someone next happens to look, which for a lot of trials means the pre-inspection scramble, not the day the gap actually opened.
Discovery Point: Manual Process vs. Continuous Monitoring
| Finding Category | Typical Discovery Point (Manual Process) | Discovery Point Under Continuous Monitoring |
|---|---|---|
| Protocol deviations | Periodic review or inspection prep | Near the visit itself |
| Inadequate study records | Cross-referenced during audit prep | As records are entered, not after |
| Consent form gaps | Found during a later document review | Checked against required elements at completion |
| Trial management / monitoring gaps | Noticed when a status report is finally compiled | Visible on an ongoing basis |
| TMF / documentation gaps | Discovered during inspection readiness review | Tracked as a running completeness metric |
| Delegation log mismatches | Found when logs are audited before inspection | Checked against current task assignments as they change |
Why the Discovery Point Matters More Than the Finding Itself
None of these six categories are exotic. Every one of them is a well-documented, long-standing feature of clinical trial conduct protocols will always have some deviations, records will always have some gaps, consent processes will always carry some risk of a missed field.
The question that actually determines whether one of these becomes a Form 483 observation, a Warning Letter, or a routine, quietly-resolved correction isn't whether the issue occurred. It's how long it sat unnoticed before someone looked.
A deviation caught the week it happens can usually be documented, explained, and closed out as part of normal trial conduct exactly the kind of routine correction regulators expect to see evidence of. The same deviation, undiscovered for four months and surfaced for the first time during inspection prep, reads very differently: not as a system working as intended, but as a system that wasn't watching. The underlying event can be identical. The regulatory story around it is not.
This is also why "we'll catch it during our next audit" has always been a weaker answer than it sounds. A periodic review only ever tells you about the gap between two points in time it was fine at the last check, and now it isn't, and nobody knows exactly when that changed. The longer that gap, the more can accumulate inside it undetected, and the harder it becomes to reconstruct a clean corrective-action story when something finally surfaces.
What Continuous, Rather Than Periodic, Oversight Actually Looks Like
Shifting from periodic to continuous oversight doesn't require a new philosophy of trial conduct it requires the existing checks to run closer to real time instead of on a monthly or pre-inspection cycle. In practice, that generally means a few specific shifts:
- Deviation and out-of-window flags surface at or near the visit, rather than being aggregated into a report reviewed weeks later.
- Study records are checked for completeness as they're entered, rather than cross-referenced in a batch during audit prep.
- Document and TMF completeness is tracked as a running metric, rather than assessed as a one-time readiness check before an inspection.
- Delegation and task assignment records are checked against current reality on an ongoing basis, rather than audited retroactively.
None of this removes the underlying judgment calls from the people running the trial a system surfacing a flag still requires someone to assess it and decide what to do. What changes is how much time exists between an issue forming and someone having the chance to act on it, which is the variable that most consistently separates a minor, well-documented correction from a finding that becomes a bigger conversation with a regulator.
Platforms built for continuous, real-time oversight Cloudbyz CTMS among them are generally designed around this same principle: connecting deviation tracking, monitoring cadence, document completeness, and delegation records to live study data, so that the gap between an issue occurring and someone having visibility into it is measured in days rather than months.
Whether any specific tool closes that gap for a given organization depends on how it's configured and used the principle above is what to evaluate any system against, not a guarantee any one platform provides on its own.
See What Continuous Visibility
If your last inspection prep involved finding gaps that had clearly existed for weeks or months, it's worth understanding what earlier visibility into these same six categories would have looked like. Book a demo with Cloudbyz
Sources
This article draws on the following published analyses of FDA and EMA clinical trial inspection findings:
- Goodwin Law, "Common FDA Bioresearch Monitoring (BIMO) Violations: Updates from FY 2023 to Now" FY2023 inspection volume and the most common clinical-investigator and sponsor/CRO findings.
- "Descriptive Analysis of Good Clinical Practice Inspection Findings from U.S. Food and Drug Administration and European Medicines Agency", PubMed Central — concordance between FDA and EMA on Protocol Compliance, Trial Management, and Documentation/TMF deficiency categories.
- Bargaje, "Good Documentation Practice in Clinical Research", PubMed Central ranking of case-history and source-documentation deficiencies in FDA and EMA investigator-site findings.
The six findings above are a synthesis drawn from these three independent analyses, not a single official ranked list published by any one regulatory agency.
Subscribe to our Newsletter
